Cancer Chemotherapy and Pharmacology

, Volume 61, Issue 5, pp 759–766 | Cite as

Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)

  • Amanda F. CashenEmail author
  • Ajit K. Shah
  • Laura Todt
  • Nicholas Fisher
  • John DiPersio
Original Article



In this study, pharmacokinetics (PK) of decitabine administered as a 3-h intravenous infusion of 15 mg/m2 every 8 h for 3 days (cycles repeated every 6 weeks) was evaluated in patients with MDS or AML.


The PK of this dosing regimen was evaluated in sixteen patients with MDS or AML. Plasma samples were obtained pre-dose and during the first 8-h dosing interval on each dosing day during Cycle 1, and at pre-dose and just prior to the end of infusion during Cycle 2. PK samples were assayed for decitabine by a sensitive and specific validated liquid chromatography-tandem mass spectrometry method.


The mean maximum observed plasma concentration (C max), 64.8–77.0 ng/ml, and the mean area under the plasma concentration-time curve (AUC0-∞), 152–163 ng h/ml, were unchanged during dosing of decitabine for 3 days. The time to the maximum concentration (T max) generally occurred at the end of infusion. The mean values for terminal phase elimination half-life (0.62–0.78 h), total body clearance (125–132 l/h per m2), and volume of distribution at steady state (62.7–89.2 l/m2), remained unchanged during the every 8 h dosing (P > 0.05). Cycles 1 and 2 C max values for days 1, 2, and 3 were not significantly different as determined by paired two-tailed t test (P > 0.05). The primary toxicity of decitabine was myelosuppression, which was observed in all patients. Two deaths, from sepsis, were considered possibly related to decitabine.


Decitabine dosed at 15 mg/m2 iv every 8 h for 3 days resulted in a predictable and manageable toxicity profile in patients with MDS/AML. The repeated dosing did not result in systemic accumulation of the drug, and decitabine PK remained unchanged from cycle to cycle.


Decitabine Myelodysplastic syndrome Acute myeloid leukemia Pharmacokinetics 


  1. 1.
    Christman JK (2002) 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 21(35):5483–5495PubMedCrossRefGoogle Scholar
  2. 2.
    Blum W, Bruner-Klisovic R, Liu S et al (2005) Phase I study of low dose decitabine in patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. Blood 106(11):#1861Google Scholar
  3. 3.
    Issa J-PJ, Garcia-Manero G, Giles FJ et al (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103(5):1635–1640PubMedCrossRefGoogle Scholar
  4. 4.
    Petti M, Mandelli F, Zagonel V et al (1993) Pilot study of 5-aza-2′-deoxycytidine (decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia 7(suppl 1):36–41PubMedGoogle Scholar
  5. 5.
    Lübbert M, Rüter B, Schmid M et al (2005) Continued low-dose decitabine (DAC) is an active first-line treatment of older aml patients: first results of a multicenter Phase II study. Blood 106(11):#1852Google Scholar
  6. 6.
    Issa J-PJ, Gharibyan V, Cortes J et al (2005) Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23(17):3948–3956PubMedCrossRefGoogle Scholar
  7. 7.
    Sacchi S, Kantarjian HM, O’Brien S et al (1999) Chronic myelogenous leukemia in nonlymphoid blastic phase. Cancer 86(12):2632–2641PubMedCrossRefGoogle Scholar
  8. 8.
    Wijermans P, Krulder J, Huijgens P, Neve P (1997) Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 11(suppl 1):S19–S23PubMedGoogle Scholar
  9. 9.
    Wijermans P, Lubbert M, Verhoef G et al (2005) An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients. Ann Hematol 84:9–17PubMedCrossRefGoogle Scholar
  10. 10.
    Wijermans P, Lubbert M, Verhoef G et al (2000) Low-dose 5-Aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter Phase II study in elderly patients. J Clin Oncol 18(5):956–962PubMedGoogle Scholar
  11. 11.
    Lubbert M, Wijermans P, Kunzmann R et al (2001) Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidine. Br J Haematol 114(2):349–357PubMedCrossRefGoogle Scholar
  12. 12.
    Kantarjian HM, Issa J-PJ, Rosenfeld C et al (2006) Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer 106(8):1794–1803PubMedCrossRefGoogle Scholar
  13. 13.
    van Groeningen C, Leyva A, O’Brien A et al (1986) Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res 46:4831–4836PubMedGoogle Scholar
  14. 14.
    Momparler R, Bouffard D, Momparler L et al (1997) Pilot phase I–II study on 5-aza-2′-deoxycytidine (decitabine) in patients with metastatic lung cancer. Anticancer Drugs 8(4):358–368PubMedCrossRefGoogle Scholar
  15. 15.
    Aparicio A, Eads CA, Leong LA et al (2003) Phase I trial of continuous infusion 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol 51(3):231–239PubMedGoogle Scholar
  16. 16.
    Rivard G, Momparler R, Demers J et al (1981) Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk Res 5:453–462PubMedCrossRefGoogle Scholar
  17. 17.
    Momparler R, Rivard G, Gyger M (1985) Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia. Pharmacol Ther 30:277–286PubMedCrossRefGoogle Scholar
  18. 18.
    Gibaldi M, Perrier D (1982) Pharmacokinetics, 2nd edn. Marcel Dekker, New York, pp 45–111Google Scholar
  19. 19.
    Cheson BD, Bennett JM, Kantarjian H et al (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96(12):3671–3674PubMedGoogle Scholar
  20. 20.
    Liu Z, Marcucci G, Byrd JC et al (2006) Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2′-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Rapid Commun Mass Spectrom 20(7):1117–1126PubMedCrossRefGoogle Scholar
  21. 21.
    Lin K, Momparler R, Rivard G (1981) High-performance liquid chromatographic analysis of chemical stability of 5-aza-2′-deoxycytidine. J Pharm Sci 70(11):1228–1232PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Amanda F. Cashen
    • 1
  • Ajit K. Shah
    • 2
  • Laura Todt
    • 1
  • Nicholas Fisher
    • 1
  • John DiPersio
    • 1
  1. 1.Department of Medicine, Division of Bone Marrow Transplantation and Stem Cell BiologyWashington University School of MedicineSt. LouisUSA
  2. 2.MGI PHARMA, Inc.BloomingtonUSA

Personalised recommendations